Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Expands By 51.4%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the target of a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 1,620,000 shares, a growth of 51.4% from the July 31st total of 1,070,000 shares. Based on an average daily trading volume, of 559,700 shares, the short-interest ratio is presently 2.9 days.

Wall Street Analyst Weigh In

BCLI has been the topic of several analyst reports. StockNews.com began coverage on shares of Brainstorm Cell Therapeutics in a report on Thursday, August 22nd. They issued a “hold” rating on the stock. Maxim Group upgraded Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Thursday, July 11th.

Brainstorm Cell Therapeutics Stock Performance

Shares of NASDAQ:BCLI remained flat at $0.32 during trading on Thursday. 98,664 shares of the stock were exchanged, compared to its average volume of 777,313. The firm has a market cap of $22.32 million, a PE ratio of -1.00 and a beta of 0.37. The firm’s fifty day moving average is $0.35 and its two-hundred day moving average is $0.43. Brainstorm Cell Therapeutics has a twelve month low of $0.13 and a twelve month high of $1.79.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). During the same quarter in the previous year, the firm earned ($0.27) earnings per share. Equities analysts anticipate that Brainstorm Cell Therapeutics will post -0.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned 0.12% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. Institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.